F9 and hemophilia B: AAV gene therapy is near clinical approval for hemophilia, a blood disorder in which clotting proteins factor VIII (hemophilia A) and factor IX (hemophilia B) do not function properly, resulting in excessive bleeding after injury and abnormal clotting [1].